https://scholars.lib.ntu.edu.tw/handle/123456789/484013
標題: | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | 作者: | YI-HSIN LIANG YU-YUN SHAO BIN-CHI LIAO Lee, Ho-Sheng CHIH-HSIN YANG Chen, Ho-Min CHUN-JU CHIANG ANN-LII CHENG Lai, Mei-Shu |
關鍵字: | Adenocarcinoma | Chemotherapy | First line | Non-small cell lung cancer | Squamous cell carcinoma;Adenocarcinoma; Chemotherapy; First line; Non-small cell lung cancer; Squamous cell carcinoma | 公開日期: | 2016 | 卷: | 7 | 期: | 11 | 來源出版物: | Journal of Cancer | 摘要: | © Ivyspring International Publisher. Aim: Cytotoxic chemotherapy is the standard first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) without specific gene alterations. This study examined the prescription pattern and the survival outcome of cytotoxic chemotherapy regimens in daily practice in Taiwan. Methods: We established a population-based cohort of patients diagnosed with advanced NSCLC between 2005 and 2009 using the databases of Taiwan Cancer Registry and National Health Insurance in Taiwan. We then analyzed chemotherapy prescriptions and the survival outcomes of patients. Results: A total of 25,008 patients with advanced NSCLC were identified, 17,443 (70.0%) of which received first-line chemotherapy and were therefore included in this study. Among them, 11,551 (66.2%) patients had adenocarcinoma and 3,292 (18.9%) patients had squamous cell carcinoma (SCC). Approximately 70% of the patients were diagnosed with NSCLC in medical centers. Platinum-based doublet chemotherapy was administered to 66.9% of the patients. Among all chemotherapy regimens, platinum with gemcitabine (33.8%) was the most common, irrespective of geographic region. The second and third most common regimens were vinorelbine alone (13.0%) and platinum with docetaxel (11.6%). The prevalence of platinum-based doublet chemotherapy regimens decreased from 71.4% in 2005 to 64.1% in 2009. Among patients with adenocarcinoma histology, those who received platinum with pemetrexed had longer OS than did patients who received other platinum-based regimens (p < 0.001). Conclusion: Our findings reaffirm that in real-world practice, treatment plans of advanced NSCLC should be drawn up according to histology type. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/484013 | ISSN: | 1837-9664 | DOI: | 10.7150/jca.15180 35859494 |
SDG/關鍵字: | antineoplastic metal complex; cytotoxic agent; docetaxel; etoposide; gemcitabine; navelbine; paclitaxel; pemetrexed; tegafur; adult; advanced cancer; aged; Article; cancer chemotherapy; cancer combination chemotherapy; cancer survival; exploratory research; female; geographic distribution; human; lung adenocarcinoma; major clinical study; male; middle aged; non small cell lung cancer; outcome assessment; overall survival; population research; prescription; squamous cell lung carcinoma; survival time; Taiwan |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。